ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MNKD MannKind Corporation

4.35
0.24 (5.84%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
MannKind Corporation NASDAQ:MNKD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.24 5.84% 4.35 4.35 4.40 4.3925 4.15 4.19 2,507,212 00:42:37

STOCK ALERT: Rosen Law Firm Reminds MannKind Corp. Investors of Important Deadline in Class Action Filed by Firm – MNKD

01/02/2016 11:23pm

Business Wire


MannKind (NASDAQ:MNKD)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more MannKind Charts.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of MannKind Corp. securities (NASDAQ:MNKD) from August 10, 2015 through January 5, 2016, all dates inclusive (the “Class Period”) of the important March 15, 2016 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks to recover damages for MannKind investors under the federal securities laws.

To join the MannKind class action, go to the firm’s website at http://rosenlegal.com/cases-808.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for more information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE

According to the lawsuit, throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) contrary to Defendants’ assurances, the mandated pulmonary testing or spirometry was still a significant issue impeding sales of Afrezza; and (2) as a result, Defendants’ statements about MannKind’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 15, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-808.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney advertising. Prior results do not guarantee a similar outcome.

The Rosen Law Firm, P.A.Laurence Rosen, Esq.Phillip Kim, Esq.Kevin Chan, Esq.275 Madison Avenue, 34th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827lrosen@rosenlegal.compkim@rosenlegal.comkchan@rosenlegal.comwww.rosenlegal.com

1 Year MannKind Chart

1 Year MannKind Chart

1 Month MannKind Chart

1 Month MannKind Chart

Your Recent History

Delayed Upgrade Clock